Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the Treatment of Antiretroviral Treatment-Experienced Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) vs. a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination With Background ART.

NCT00298350 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00298350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00298350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the Treatment of Antiretroviral Treatment-Experienced Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) vs. a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination With Background ART.
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
July 31, 2007
Enrollment
278 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, hiv-1, human immunodeficiency virus